Edgewise Therapeutics, INC Form 4 insider transactions

Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics, exercised stock options and sold 10,000 shares of common stock on February 5, 2025.

Edgewise Therapeutics' Chief Medical Officer, Joanne M. Donovan, exercised stock options and sold 25,000 shares of common stock on January 28, 2025, under a pre-arranged 10b5-1 trading plan.

Robert Blaustein, Chief Development Officer of Edgewise Therapeutics, was granted 160,000 stock options and 30,000 restricted stock units on January 21, 2025.

Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, exercised stock options and sold 100,000 shares of common stock on December 30, 2024.

Marc Semigran, Chief Development Officer of Edgewise Therapeutics, exercised stock options and sold shares on December 24, 2024, according to a Form 4 filing.

R. Michael Carruthers, CFO of Edgewise Therapeutics, exercised stock options and acquired 70,000 shares of common stock at $0.71 per share on October 11, 2024.

Alan J. Russell, Chief Scientific Officer of Edgewise Therapeutics, exercised stock options and sold shares on September 20, 2024.

John R. Moore, General Counsel of Edgewise Therapeutics, exercised stock options and sold shares of common stock on September 20 and 23, 2024.

Joanne M. Donovan, CMO of Edgewise Therapeutics, sold 7,162 shares of common stock at an average price of $28.2886 on September 20, 2024.

Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics, exercised stock options and sold shares on September 20, 2024.

R. Michael Carruthers, CFO of Edgewise Therapeutics, exercised stock options and sold shares on September 20, 2024, according to a Form 4 filing.

Marc Semigran, Chief Development Officer of Edgewise Therapeutics, receives stock options and restricted stock units as part of compensation.

Alan J. Russell, Chief Scientific Officer of Edgewise Therapeutics, acquired stock options and restricted stock units on August 12, 2024, according to a Form 4 filing.

John R. Moore, General Counsel of Edgewise Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) on August 12, 2024.

Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) on August 12, 2024.

Kevin Koch, CEO of Edgewise Therapeutics, reports the acquisition of stock options and restricted stock units.

Joanne M. Donovan, CMO of Edgewise Therapeutics, reports the acquisition of stock options and restricted stock units.

R. Michael Carruthers, CFO of Edgewise Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) on August 12, 2024.

Director Peter Thompson acquired 20,594 stock options in Edgewise Therapeutics on June 10, 2024.

Director Jonathan C Fox acquired 20,594 stock options in Edgewise Therapeutics, Inc. on June 10, 2024.

Director Arlene Morris of Edgewise Therapeutics, Inc. reports the acquisition of stock options.

Director Laura Brege reports the acquisition of stock options in Edgewise Therapeutics.

Director Badreddin Edris of Edgewise Therapeutics reports the acquisition of stock options.

Director Jonathan Root acquired 20,594 stock options in Edgewise Therapeutics on June 10, 2024.

Director Arlene Morris acquired 34,311 stock options in Edgewise Therapeutics, Inc. on May 6, 2024, according to a Form 4 filing.

John R. Moore, General Counsel of Edgewise Therapeutics, sold shares to cover statutory tax withholding obligations related to vesting Restricted Stock Units.

R. Michael Carruthers, CFO of Edgewise Therapeutics, reports the acquisition and disposal of company stock, including shares sold to cover tax obligations related to vesting restricted stock units.

Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics, sold shares to cover statutory tax withholding obligations related to vesting Restricted Stock Units.

Alan J. Russell, Chief Scientific Officer of Edgewise Therapeutics, reports the acquisition and disposal of company stock, including shares acquired through restricted stock units and sales to cover tax obligations.

Joanne M. Donovan, CMO of Edgewise Therapeutics, reports the acquisition and disposition of company stock, including shares acquired through RSU vesting and sales to cover tax obligations.